Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Grant | Alive

Total Raised


About Pre Diagnostics

Pre Diagnostics is a Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company's proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients.

Pre Diagnostics Headquarters Location


Oslo, 0115,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pre Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pre Diagnostics is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Latest Pre Diagnostics News

PreADx Alzheimer’s Detection Immunoassay Proof of Concept Study Successful

Apr 1, 2021

Pre Diagnostics, an Oslo, Norway-based healthtech company developing novel blood tests for neurodegenerative diseases, announced that its PreADx immunoassay for early detection of Alzheimer’s Disease has successfully completed a clinical evaluation. The company now plans to further optimize the assay in advance of CE marking in Q2, 2021. Unlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes. The monocytes are a part of the innate immune system, and stem from the same cell lineage as the microglia and macrophages that clear plaques in the brain. In the blind evaluation of 62 well-characterized samples and controls from the Norwegian multicenter study “Dementia Disease Initiative,” PreADx achieved an ROC AUC of .81 in distinguishing healthy controls from Alzheimer’s patients. This is in line with the generally recognized threshold for diagnostic accuracy and opens the way for development of a much-needed new wave of early Alzheimer’s Disease assays. “In both my clinical work and the Dementia Disease Initiative, I have seen the pressing need for more early diagnostic tools. I am pleased to see that the concept of extracting relevant information about neurodegenerative diseases from monocytes first discovered back in 2009, now has been validated in this study. I believe integrating AD diagnostics with innate immunity may also be helpful for precision medicine strategies,” says Professor Tormod Fladby, MD PhD, main inventor and head of the Department of Neurology at Akershus University Hospital. “Beta-amyloid aggregation is generally considered the first pathological sign of the disease which is why we believe that a validated non-invasive immunoassay that can detect this will prove an invaluable front-line tool for improving Alzheimer’s Disease detection and treatment,” says Charlotte Berg-Svendsen, CCO, Pre Diagnostics AS. “In preparation for CE marking we will now run further samples using an optimized version of the assay, which should also lead to increased accuracy. Further analysis will also give us a better picture of the potential clinical utility of this new biomarker, both alone and in combination with gender, ApoE and age.” This development project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 849834. Share:

Pre Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pre Diagnostics Rank

  • Where is Pre Diagnostics's headquarters?

    Pre Diagnostics's headquarters is located at Vika, Oslo.

  • What is Pre Diagnostics's latest funding round?

    Pre Diagnostics's latest funding round is Grant.

  • How much did Pre Diagnostics raise?

    Pre Diagnostics raised a total of $1.6M.

  • Who are the investors of Pre Diagnostics?

    Investors of Pre Diagnostics include Horizon 2020.

  • Who are Pre Diagnostics's competitors?

    Competitors of Pre Diagnostics include iLoF.

You May Also Like


Probius is an all-electronic platform for fingerprinting of biological specimens in preclinical and food safety applications.

lino Biotech

lino Biotech provides focal molography, which is a novel label-free biosensor platform for direct imaging of biomolecular interactions in living cells.


Lasers4Life seeks to develop a method based on the unique properties of ultrashort laser pulses that will enable doctors to diagnose cancers at the earliest possible stage.

iLoF Logo

iLoF enables a new era of personalized medicine by using AI and photonics to build a cloud-based library of disease biomarkers and biological profiles. It is enabling biotechs and pharmaceutical companies to make clinical trials faster, cheaper, and more patient-centric. The platform pulls together massive amounts of data to build a library of biological profiles, bringing together physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. The company was founded in 2019 and is based in London, England.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.